Cysteamine | CAS#60-23-1 | aminothiol

MedKoo Cat#: 596389 | Name: Cysteamine

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cysteamine is a medication intended for a number of indications, and approved by the FDA to treat cystinosis. It is stable aminothiol, i.e., an organic compound containing both an amine and a thiol functional groups. Cysteamine is a white, water-soluble solid. It is often used as salts of the ammonium derivative [HSCH2CH2NH3]+ including the hydrochloride, phosphocysteamine, and bitartrate.

Chemical Structure

Cysteamine

CAS#60-23-1

Theoretical Analysis

MedKoo Cat#: 596389

Name: Cysteamine

CAS#: 60-23-1

Chemical Formula: C2H7NS

Exact Mass: 77.0299

Molecular Weight: 77.14

Elemental Analysis: C, 31.14; H, 9.15; N, 18.16; S, 41.56

Price and Availability

Size	Price	Availability	Quantity
5g	USD 250.00	2 Weeks
25g	USD 450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Cysteamine; Cystagon; Becaptan; 2-Aminoethanethiol; 2-Aminoethyl mercaptan; L 1573; L-1573; L1573; NSC 647528; NSC-647528; NSC647528;

IUPAC/Chemical Name

2-aminoethane-1-thiol; Cysteamine

InChi Key

UFULAYFCSOUIOV-UHFFFAOYSA-N

InChi Code

InChI=1S/C2H7NS/c3-1-2-4/h4H,1-3H2

SMILES Code

NCCS

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2930.90.9135

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 77.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Conjeevaram Selvakumar PK, Kabbany MN, Alkhouri N. Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter. Paediatr Drugs. 2018 May 9. doi: 10.1007/s40272-018-0292-2. [Epub ahead of print] Review. PubMed PMID: 29740791. 2: Kaufeld J, Weber LT, Kurschat C, Canaan-Kuehl S, Brand E, Oh J, Pape L. [Cystinosis : Diagnosis, cystine-depleting therapy, and transition]. Internist (Berl). 2018 Apr 18. doi: 10.1007/s00108-018-0416-3. [Epub ahead of print] Review. German. PubMed PMID: 29671012. 3: Lv W, Booz GW, Fan F, Wang Y, Roman RJ. Oxidative Stress and Renal Fibrosis: Recent Insights for the Development of Novel Therapeutic Strategies. Front Physiol. 2018 Feb 16;9:105. doi: 10.3389/fphys.2018.00105. eCollection 2018. Review. PubMed PMID: 29503620; PubMed Central PMCID: PMC5820314. 4: Chiew AL, Gluud C, Brok J, Buckley NA. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev. 2018 Feb 23;2:CD003328. doi: 10.1002/14651858.CD003328.pub3. Review. PubMed PMID: 29473717. 5: Makuloluwa AK, Shams F. Cysteamine hydrochloride eye drop solution for the treatment of corneal cystine crystal deposits in patients with cystinosis: an evidence-based review. Clin Ophthalmol. 2018 Jan 24;12:227-236. doi: 10.2147/OPTH.S133516. eCollection 2018. Review. PubMed PMID: 29416314; PubMed Central PMCID: PMC5789046. 6: Ariceta G, Giordano V, Santos F. Effects of long-term cysteamine treatment in patients with cystinosis. Pediatr Nephrol. 2017 Dec 19. doi: 10.1007/s00467-017-3856-4. [Epub ahead of print] Review. PubMed PMID: 29260317. 7: Nesterova G, Gahl WA. Cystinosis. 2001 Mar 22 [updated 2017 Dec 7]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from http://www.ncbi.nlm.nih.gov/books/NBK1400/ PubMed PMID: 20301574. 8: Gawrieh S, Chalasani N. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Liver Dis. 2018 Feb;22(1):189-199. doi: 10.1016/j.cld.2017.08.013. Epub 2017 Oct 10. Review. PubMed PMID: 29128056. 9: Deb A, Frank S, Testa CM. New symptomatic therapies for Huntington disease. Handb Clin Neurol. 2017;144:199-207. doi: 10.1016/B978-0-12-801893-4.00017-1. Review. PubMed PMID: 28947118. 10: Smith WD, Bardin E, Cameron L, Edmondson CL, Farrant KV, Martin I, Murphy RA, Soren O, Turnbull AR, Wierre-Gore N, Alton EW, Bundy JG, Bush A, Connett GJ, Faust SN, Filloux A, Freemont PS, Jones AL, Takats Z, Webb JS, Williams HD, Davies JC. Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis. FEMS Microbiol Lett. 2017 Aug 1;364(14). doi: 10.1093/femsle/fnx121. Review. PubMed PMID: 28854668. 11: McBean GJ. Cysteine, Glutathione, and Thiol Redox Balance in Astrocytes. Antioxidants (Basel). 2017 Aug 3;6(3). pii: E62. doi: 10.3390/antiox6030062. Review. PubMed PMID: 28771170; PubMed Central PMCID: PMC5618090. 12: Medic G, van der Weijden M, Karabis A, Hemels M. A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis. Curr Med Res Opin. 2017 Nov;33(11):2065-2076. doi: 10.1080/03007995.2017.1354288. Epub 2017 Aug 3. Review. PubMed PMID: 28692321. 13: Gallego-Villar L, Hannibal L, Häberle J, Thöny B, Ben-Omran T, Nasrallah GK, Dewik AN, Kruger WD, Blom HJ. Cysteamine revisited: repair of arginine to cysteine mutations. J Inherit Metab Dis. 2017 Jul;40(4):555-567. doi: 10.1007/s10545-017-0060-4. Epub 2017 Jun 22. Review. PubMed PMID: 28643139; PubMed Central PMCID: PMC5740875. 14: Enns GM, Cowan TM. Glutathione as a Redox Biomarker in Mitochondrial Disease-Implications for Therapy. J Clin Med. 2017 May 3;6(5). pii: E50. doi: 10.3390/jcm6050050. Review. PubMed PMID: 28467362; PubMed Central PMCID: PMC5447941. 15: Mariani F, Roncucci L. Role of the Vanins-Myeloperoxidase Axis in Colorectal Carcinogenesis. Int J Mol Sci. 2017 Apr 27;18(5). pii: E918. doi: 10.3390/ijms18050918. Review. PubMed PMID: 28448444; PubMed Central PMCID: PMC5454831. 16: Sarkar B, Kulharia M, Mantha AK. Understanding human thiol dioxygenase enzymes: structure to function, and biology to pathology. Int J Exp Pathol. 2017 Apr;98(2):52-66. doi: 10.1111/iep.12222. Epub 2017 Apr 24. Review. PubMed PMID: 28439920; PubMed Central PMCID: PMC5485369. 17: Song M, Hwang H, Im CY, Kim SY. Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors. J Med Chem. 2017 Jan 26;60(2):554-567. doi: 10.1021/acs.jmedchem.6b01036. Epub 2016 Nov 21. Review. PubMed PMID: 28122456. 18: Veys KR, Elmonem MA, Arcolino FO, van den Heuvel L, Levtchenko E. Nephropathic cystinosis: an update. Curr Opin Pediatr. 2017 Apr;29(2):168-178. doi: 10.1097/MOP.0000000000000462. Review. PubMed PMID: 28107209. 19: Cherqui S, Courtoy PJ. The renal Fanconi syndrome in cystinosis: pathogenic insights and therapeutic perspectives. Nat Rev Nephrol. 2017 Feb;13(2):115-131. doi: 10.1038/nrneph.2016.182. Epub 2016 Dec 19. Review. PubMed PMID: 27990015; PubMed Central PMCID: PMC5657490. 20: Franke J, Hertweck C. Biomimetic Thioesters as Probes for Enzymatic Assembly Lines: Synthesis, Applications, and Challenges. Cell Chem Biol. 2016 Oct 20;23(10):1179-1192. doi: 10.1016/j.chembiol.2016.08.014. Epub 2016 Sep 29. Review. PubMed PMID: 27693058.